TerrencePCesconMD

Oncology • West Reading, PA

RPS hematology oncology

Join to view full profile

Dr. Cescon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Cescon's full profile

Already have an account?

Office
6th Avenue And Spruce Street
Trhmc Regional Cancer Center N Ground
West Reading, PA 19611
Phone+1 484-628-0900

Fax+1 610-374-2677
Is this information wrong?

Education & Training

Drexel University College of Medicine/Hahnemann University HospitalFellowship, Hematology and Medical Oncology, 1991 - 1994
Drexel University College of Medicine/Hahnemann University HospitalResidency, Internal Medicine, 1988 - 1991
Drexel University College of MedicineClass of 1988

Certifications & Licensure

PA State Medical License 1991 - 2024

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc., 2012-2013

Clinical Trials

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Start of enrollment: 2008 Nov 10
Active, not recruiting
Phase 3
Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis Start of enrollment: 2009 Nov 01
Completed
Phase 3
Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction Start of enrollment: 2009 Jan 21
Terminated
Phase 1, Phase 2
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
S0820, Adenoma and Second Primary Prevention Trial Start of enrollment: 2013 Aug 23
Active, not recruiting
Phase 3
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2012 Sep 28
Completed
Phase 1, Phase 2
S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer Start of enrollment: 2013 Sep 12
Active, not recruiting
Phase 3
Study of Fulvestrant +/- Everolimus in Post-Menopausal, Hormone-Receptor + Metastatic Breast Ca Resistant to AI Start of enrollment: 2013 May 31
Completed
Phase 2
S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer Start of enrollment: 2013 Mar 08
Active, not recruiting
Phase 3
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer Start of enrollment: 2013 Apr 25
Completed
Phase 2
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
Active, not recruiting
Phase 2
Standard or Comprehensive Radiation Therapy in Treating Patients With Early-Stage Breast Cancer Previously Treated With Chemotherapy and Surgery Start of enrollment: 2013 Aug 01
Active, not recruiting
Not Applicable
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma Start of enrollment: 2013 Dec 01
Terminated
Phase 2
Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Jan 24
Active, not recruiting
Phase 2
Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer Start of enrollment: 2014 Jan 15
Active, not recruiting
Phase 3
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Active, not recruiting
Phase 3
Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic Start of enrollment: 2014 Mar 29
Active, not recruiting
Phase 3
Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAF Mutant Melanoma That Cannot Be Removed by Surgery Start of enrollment: 2014 Sep 19
Active, not recruiting
Phase 2
A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma Start of enrollment: 2015 Nov 23
Recruiting
Phase 2, Phase 3
Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel With or Without Carboplatin in Treating Patients With Triple-Negative Breast Cancer Start of enrollment: 2015 Jul 26
Recruiting
Phase 3
Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches Start of enrollment: 2014 Nov 01
Completed
Phase 2
Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Start of enrollment: 2014 Sep 01
Completed
Phase 2, Phase 3
Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers Start of enrollment: 2015 Dec 29
Active, not recruiting
Phase 3
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer Start of enrollment: 2017 Jan 18
Active, not recruiting
Phase 3
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) Start of enrollment: 2019 Jul 26
Active, not recruiting
Phase 3
Molecular Genetics Studies of Cancer Patients and Their Relatives Start of enrollment: 1997 Apr 18
Recruiting
Join now to see all

Publications & Presentations

PubMed

1 citations
Genomic Aberrations in Circulating Tumor DNAs from Palbociclib-Treated Metastatic Breast Cancer Patients Reveal a Novel Resistance Mechanism.
Maysa Abu-Khalaf, Chun Wang, Zhenchao Zhang, Rui Luo, Weelic Chong, Daniel P Silver, Frederick Fellin, Rebecca Jaslow, AnaMaria Lopez, Terrence Cescon, Wei Jiang, Rona...> ;Cancers. 2022 Jun 10
6 citations
Breast cancer associated pathogenic variants among women 61 years and older with triple negative breast cancer.
Yanin Chavarri-Guerra, Catherine A. Marcum, Carolyn B. Hendricks, Deborah Wilbur, Terrence P. Cescon, Christopher R. Hake, Julio Abugattas, Yenni P. Rodriguez, Cynthia...> ;Journal of Geriatric Oncology. 2021 Jun 1
22 citations
Prognostic value of HER2 status on circulating tumor cells in advanced-stage breast cancer patients with HER2-negative tumors.
Chun Wang, Zhaomei Mu, Zhong Ye, Zhenchao Zhang, Maysa M. Abu-Khalaf, Daniel P. Silver, Juan P. Palazzo, Geetha Jagannathan, Frederick M. Fellin, Saveri Bhattacharya, ...> ;Breast Cancer Research and Treatment. 2020 May 4
12 citations
A Three-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408.
Andrew M. Evens, Fangxin Hong, Thomas M. Habermann, Ranjana H. Advani, Randy D. Gascoyne, Thomas E. Witzig, Andrew Quon, Erik A. Ranheim, Stephen M. Ansell, Puneet Sin...> ;Clinical Cancer Research. 2020 Jan 1
12 citations
Multi-institutional phase I study of low-dose ultra-fractionated radiotherapy as a chemosensitizer for gemcitabine and erlotinib in patients with locally advanced or l...
Andre Konski, Joshua E. Meyer, Michael C. Joiner, Michael J. Hall, Philip A. Philip, Anthony F. Shields, E. McSpadden, Minsig Choi, Beth Adaire, Gail Duncan, Neal J. M...> ;Radiotherapy and Oncology. 2014 Oct 1
34 citations
Axitinib and/or bevacizumab with modified FOLFOX-6 as first-line therapy for metastatic colorectal cancer: a randomized phase 2 study.
Jeffrey R. Infante, Tony R. Reid, Allen Lee Cohn, William Jeffery Edenfield, Terrence P. Cescon, John T. Hamm, Imtiaz Malik, Thomas A. Rado, Philip J. McGee, Donald A....> ;Cancer. 2013 Jul 15
66 citations
Preparing individuals to communicate genetic test results to their relatives: report of a randomized control trial
Susan Montgomery, Andrea M. Barsevick, Brian L. Egleston, Ruth Bingler, Karen Ruth, Suzanne M. Miller, John Malick, Terrence P. Cescon, Mary B. Daly> ;Familial Cancer. 2013 Feb 19
43 citations
Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III ...
John D. Hainsworth, David R. Spigel, Bobby L. Clark, Dianna Shipley, Dana S. Thompson, C. Farley, Kimberly West-Osterfield, Cassie M. Lane, Terrence Cescon, Martin J. ...> ;Cancer Journal. 2010 Jan 1
35 citations
Intention to communicate BRCA1/BRCA2 genetic test results to the family.
Andrea M. Barsevick, Susan Montgomery, Karen Ruth, Eric A. Ross, Brian L. Egleston, Ruth Bingler, John Malick, Suzanne M. Miller, Terrence P. Cescon, Mary B. Daly> ;Journal of Family Psychology. 2008 Apr 1
27 citations
Prostate cancer risk assessment program: a 10-year update of cancer detection.
Veda N. Giri, Jennifer L. Beebe-Dimmer, Mark K. Buyyounouski, Andre Konski, Steven J. Feigenberg, Robert G. Uzzo, Gerald E. Hanks, Andrew K. Godwin, David Y.T. Chen, R...> ;The Journal of Urology. 2007 Nov 1
16 citations
A phase II clinical trial of ZD1839 (Iressa) in combination with docetaxel as first-line treatment in patients with advanced breast cancer.
Sheri K. Dennison, Samuel A. Jacobs, John W Wilson, Janell Seeger, Terrence P. Cescon, Jane M. Raymond, Charles E. Geyer, Norman Wolmark, Sandra M. Swain> ;Investigational New Drugs. 2007 Jun 12
20 citations
Pemetrexed/oxaliplatin for first-line treatment of patients with advanced colorectal cancer: a phase II trial of the National Surgical Adjuvant Breast and Bowel Projec...
James N. Atkins, Samuel A. Jacobs, H. Samuel Wieand, Roy E. Smith, William J. John, Linda H. Colangelo, Victor G. Vogel, J. Philip Kuebler, Terrence P. Cescon, Barbara...> ;Clinical Colorectal Cancer. 2005 Sep 1
Join now to see all